Back to Archived Journals » Gastrointestinal Cancer: Targets and Therapy » Volume 6

Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: utility and experience from the clinic

Authors Kundranda M, Dragovich T

Received 9 September 2015

Accepted for publication 14 November 2015

Published 14 January 2016 Volume 2016:6 Pages 13—20

DOI https://doi.org/10.2147/GICTT.S82103

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Sonal Gupta

Peer reviewer comments 3

Editor who approved publication: Dr Eileen O'Reilly


Madappa N Kundranda, Tomislav Dragovich

Division of Hematology and Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA

Abstract: Pancreatic ductal adenocarcinoma remains one of the deadliest epithelial cancers, primarily due to late diagnosis, early metastasis and the lack of effective treatments. With recent advances in systemic therapies, the median survival for metastatic disease has essentially doubled to approximately 1 year, and a significant number of patients are receiving multiple lines of therapy. One such first-line therapy is the combination of gemcitabine with nab-paclitaxel, which was approved by the US Food and Drug Administration in 2013. This standard option is now serving as a backbone to other novel combinations. In this review, we focus on the development of this combination, its clinical utility, and real-life experiences of managing patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine and nab-paclitaxel.

Keywords: pancreatic ductal adenocarcinoma, nab-paclitaxel, MPACT trial, PRODIGE 4/ACCORD 11 trial

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]